Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
AMD Shares Slide Despite Earnings Beat as Cautious Revenue Outlook Weighs on Stock 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate 
Nintendo Shares Slide After Earnings Miss Raises Switch 2 Margin Concerns 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
HAUPPAUGE, N.Y., March 23, 2017 -- United-Guardian, Inc., (NASDAQ:UG) reported FY-2016 net income of $2,581,142 ($0.56 per share) on net sales of $10,776,867, as compared with net income of $4,606,929 ($1.00 per share) on net sales of $14,006,244 in 2015.
Ken Globus, President of United-Guardian, stated, “Our revenue for the first eight months of 2016 was negatively impacted by a regulatory issue in China that was unrelated to our product but caused a significant overstock situation for one of our products in China. That regulatory issue and overstock situation have been resolved, and shipments to China resumed in September. As a result, we are anticipating an increase in China sales in 2017. We began selling our new single-dose form of Renacidin® Irrigation, our most important pharmaceutical product, in April 2016, and we believe that sales of that product will increase as the year progresses. We are also very excited about our latest cosmetic ingredient, Lubrajel® Marine, which is being launched globally by ASI, our largest marketing partner, at the international In-Cosmetics conference in London in April. We are hopeful that this product will begin to contribute to our sales by the end of 2017, and that this new addition to our product line, along with the resumption of sales into China and the anticipated increase in Renacidin sales, will result in a stronger and more profitable year for us in 2017.”
United-Guardian is a manufacturer of cosmetic ingredients, personal and health care products, pharmaceuticals, and specialty industrial products.
NOTE: This press release contains both historical and "forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements about the company’s expectations or beliefs concerning future events, such as financial performance, business prospects, and similar matters, are being made in reliance upon the “safe harbor” provisions of that Act. Such statements are subject to a variety of factors that could cause the company's actual results or performance to differ materially from the anticipated results or performance expressed or implied by such forward-looking statements. For further information about the risks and uncertainties that may affect the company’s business please refer to the company's reports and filings with the Securities and Exchange Commission.
| RESULTS FOR THE YEARS ENDED | ||||||
| DECEMBER 31, 2016 AND DECEMBER 31, 2015 | ||||||
| STATEMENTS OF INCOME | ||||||
| Years ended December 31, | ||||||
| 2016 | 2015 | |||||
| Net sales | $ | 10,776,867 | $ | 14,006,244 | ||
| Costs and expenses: | ||||||
| Cost of sales | 4,882,644 | 5,202,158 | ||||
| Operating expenses | 1,852,833 | 1,862,290 | ||||
| Research and development | 651,828 | 648,211 | ||||
| Total costs and expenses | 7,387,305 | 7,712,659 | ||||
| Income from operations | 3,389,562 | 6,293,585 | ||||
| Other income (expense): | ||||||
| Investment income | 306,505 | 332,705 | ||||
| Loss from sale of asset | --- | (879 | ) | |||
| Total other income | 306,505 | 331,826 | ||||
| Income from operations before provision for | 3,696,067 | 6,625,411 | ||||
| income taxes | ||||||
| Provision for income taxes | 1,114,925 | 2,018,482 | ||||
| Net income | $ | 2,581,142 | $ | 4,606,929 | ||
| Earnings per common share (basic and diluted) | $ | 0.56 | $ | 1.00 | ||
| Weighted average shares (basic and diluted) | 4,594,319 | 4,594,319 | ||||
| BALANCE SHEET DATA | ||||
| (condensed) | ||||
| December 31, | ||||
| 2016 | 2015 | |||
| Current assets | $ | 13,968,689 | $ | 14,517,960 |
| Net property, plant, and equipment | 1,090,591 | 1,096,113 | ||
| Other asset(s) (net) | 59,295 | 74,118 | ||
| Total assets | $ | 15,118,575 | $ | 15,688,191 |
| Current liabilities | $ | 1,045,951 | $ | 988,367 |
| Deferred income taxes | 252,135 | 118,010 | ||
| Total Liabilities | $ | 1,298,086 | $ | 1,106,377 |
| $ | 13,820,489 | $ | 14,581,814 | |
| Stockholders’ equity | ||||
| Total liabilities and stockholders’ equity | $ | 15,118,575 | $ | 15,688,191 |
Contact: Robert S. Rubinger (631) 273-0900
